484 related articles for article (PubMed ID: 16505010)
1. Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study.
Kadkol SS; Lin AY; Barak V; Kalickman I; Leach L; Valyi-Nagy K; Majumdar D; Setty S; Maniotis AJ; Folberg R; Pe'er J
Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):802-6. PubMed ID: 16505010
[TBL] [Abstract][Full Text] [Related]
2. Serum markers to detect metastatic uveal melanoma.
Barak V; Frenkel S; Kalickman I; Maniotis AJ; Folberg R; Pe'er J
Anticancer Res; 2007; 27(4A):1897-900. PubMed ID: 17649791
[TBL] [Abstract][Full Text] [Related]
3. Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study.
Reiniger IW; Wolf A; Welge-Lüssen U; Mueller AJ; Kampik A; Schaller UC
Am J Ophthalmol; 2007 Apr; 143(4):705-7. PubMed ID: 17386288
[TBL] [Abstract][Full Text] [Related]
4. "Melanoma inhibitory activity" (MIA): a promising serological tumour marker in metastatic uveal melanoma.
Reiniger IW; Schaller UC; Haritoglou C; Hein R; Bosserhoff AK; Kampik A; Mueller AJ
Graefes Arch Clin Exp Ophthalmol; 2005 Nov; 243(11):1161-6. PubMed ID: 15906071
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin and 'melanoma inhibitory activity': comparison of two serological tumor markers in metastatic uveal melanoma patients.
Haritoglou I; Wolf A; Maier T; Haritoglou C; Hein R; Schaller UC
Ophthalmologica; 2009; 223(4):239-43. PubMed ID: 19270465
[TBL] [Abstract][Full Text] [Related]
6. Melanoma inhibitory activity: a novel serum marker for uveal melanoma.
Schaller UC; Bosserhoff AK; Neubauer AS; Buettner R; Kampik A; Mueller AJ
Melanoma Res; 2002 Dec; 12(6):593-9. PubMed ID: 12459649
[TBL] [Abstract][Full Text] [Related]
7. Potential Role of Soluble c-Met as a New Candidate Biomarker of Metastatic Uveal Melanoma.
Barisione G; Fabbi M; Gino A; Queirolo P; Orgiano L; Spano L; Picasso V; Pfeffer U; Mosci C; Jager MJ; Ferrini S; Gangemi R
JAMA Ophthalmol; 2015 Sep; 133(9):1013-21. PubMed ID: 26068448
[TBL] [Abstract][Full Text] [Related]
8. Using the direct-injection model of early uveal melanoma hepatic metastasis to identify TPS as a potentially useful serum biomarker.
Barak V; Frenkel S; Valyi-Nagy K; Leach L; Apushkin MA; Lin AY; Kalickman I; Baumann NA; Pe'er J; Maniotis AJ; Folberg R
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4399-402. PubMed ID: 17898257
[TBL] [Abstract][Full Text] [Related]
9. Tumor cell plasticity in uveal melanoma: microenvironment directed dampening of the invasive and metastatic genotype and phenotype accompanies the generation of vasculogenic mimicry patterns.
Folberg R; Arbieva Z; Moses J; Hayee A; Sandal T; Kadkol S; Lin AY; Valyi-Nagy K; Setty S; Leach L; Chévez-Barrios P; Larsen P; Majumdar D; Pe'er J; Maniotis AJ
Am J Pathol; 2006 Oct; 169(4):1376-89. PubMed ID: 17003493
[TBL] [Abstract][Full Text] [Related]
10. The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1).
Barak V; Kaiserman I; Frenkel S; Hendler K; Kalickman I; Pe'er J
Anticancer Res; 2011 Jan; 31(1):345-9. PubMed ID: 21273622
[TBL] [Abstract][Full Text] [Related]
11. VEGF as a biomarker for metastatic uveal melanoma in humans.
Barak V; Pe'er J; Kalickman I; Frenkel S
Curr Eye Res; 2011 Apr; 36(4):386-90. PubMed ID: 21284506
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of chemokine receptors on uveal melanoma cells and their metastases.
Li H; Alizadeh H; Niederkorn JY
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):636-43. PubMed ID: 18235009
[TBL] [Abstract][Full Text] [Related]
13. [Melanoma inhibitory activity (MIA). Evaluation of a new tumor-associated antigen as a serum marker for uveal melanomas].
Schaller UC; Mueller AJ; Bosserhoff AK; Haraida S; Löhrs U; Buettner R; Kampik A
Ophthalmologe; 2000 Jun; 97(6):429-32. PubMed ID: 10916387
[TBL] [Abstract][Full Text] [Related]
14. Trends in liver function tests: a comparison with serum tumor markers in metastatic uveal melanoma (part 2).
Hendler K; Pe'er J; Kaiserman I; Baruch R; Kalickman I; Barak V; Frenkel S
Anticancer Res; 2011 Jan; 31(1):351-7. PubMed ID: 21273623
[TBL] [Abstract][Full Text] [Related]
15. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests.
Missotten GS; Korse CM; van Dehn C; Linders TC; Keunen JE; Jager MJ; Bonfrer JM
Tumour Biol; 2007; 28(2):63-9. PubMed ID: 17264538
[TBL] [Abstract][Full Text] [Related]
16. Distinguishing fibrovascular septa from vasculogenic mimicry patterns.
Lin AY; Maniotis AJ; Valyi-Nagy K; Majumdar D; Setty S; Kadkol S; Leach L; Pe'er J; Folberg R
Arch Pathol Lab Med; 2005 Jul; 129(7):884-92. PubMed ID: 15974811
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of circulating tumor cells in metastatic uveal melanoma.
Schuster R; Bechrakis NE; Stroux A; Busse A; Schmittel A; Thiel E; Foerster MH; Keilholz U
Oncology; 2011; 80(1-2):57-62. PubMed ID: 21625180
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma.
Schuster R; Bechrakis NE; Stroux A; Busse A; Schmittel A; Scheibenbogen C; Thiel E; Foerster MH; Keilholz U
Clin Cancer Res; 2007 Feb; 13(4):1171-8. PubMed ID: 17317826
[TBL] [Abstract][Full Text] [Related]
19. Inhibitor of apoptosis proteins gene expression and its correlation with prognostic factors in primary and metastatic uveal melanoma.
Lederman M; Meir T; Zeschnigk M; Pe'er J; Chowers I
Curr Eye Res; 2008 Oct; 33(10):876-84. PubMed ID: 18853322
[TBL] [Abstract][Full Text] [Related]
20. [Expression of EphA2 in Metastatic and Non-Metastatic Primary Uveal Melanoma].
Vukoja V; Brandenbusch T; Tura A; Nassar K; Rohrbach DJ; Lüke M; Grisanti S; Lüke J
Klin Monbl Augenheilkd; 2016 Mar; 232(3):290-7. PubMed ID: 26854480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]